This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brophy, J. M.
Right arrow Articles by Brassard, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brophy, J. M.
Right arrow Articles by Brassard, P.
Related Collections
Right arrow Vascular surgery
Right arrow Drugs: cardiovascular system
CMAJ • November 25, 2003; 169 (11)
© 2003 Canadian Medical Association or its licensors

Research
Recherche

The use of cholesterol-lowering medications after coronary revascularization

James M. Brophy, Chantal Bourgault and Paul Brassard

From the Department of Medicine, McGill University Health Center, McGill University, Montréal, Que.

Correspondence to: Dr. James Brophy, Clinical Epidemiology, McGill University Health Center, Royal Victoria Hospital, 687 Pine Ave. W, Room R4.12, Montréal QC H3A 1A1; fax 514 843-1493; james.brophy{at}mcgill.ca

Background: In clinical trials, cholesterol-lowering medications have been proven to decrease mortality and morbidity and are strongly recommended as secondary prevention for patients with established coronary artery disease. Whether physicians and patients follow this recommendation is unknown. Our objective was to determine the rate at which patients fill at least one prescription for cholesterol-lowering medications after coronary revascularization.

Methods: Using the computerized administrative databases of the Régie de l'assurance maladie du Québec, we identified all elderly patients (older than 65 years) who had a coronary revascularization procedure (percutaneous coronary intervention or coronary artery bypass graft) between Apr. 1, 1995, and Dec. 31, 1997, and who survived until hospital discharge. We also determined the percentage of these patients who filled one or more prescriptions for cholesterol-lowering drug therapy before Dec. 31, 1999, or death, whichever date came first. We used multivariate logistic regression models to examine the independent associations between filling a prescription for a cholesterol-lowering drug, patient characteristics and the type and year of coronary revascularization.

Results: We identified 11 958 elderly patients who had a coronary revascularization between Apr. 1, 1995, and Dec. 31, 1997. During a follow-up period that averaged 3 years, 4443 (37.2%) patients did not fill a prescription for a cholesterol-lowering medication. Patients who were male, of advanced age, who had diabetes or congestive heart failure were less likely to fill a prescription for a cholesterol-lowering medication. Patients whose initial revascularization procedure was coronary artery bypass grafting were also less likely than those who had angioplasty to start cholesterol-lowering medication (relative risk [RR] 0.77, 95% confidence interval [CI] 0.73 – 0.81). Use of cholesterol lowering medications before the revascularization procedure was very strongly associated with future drug use (RR 7.20, 95% CI 6.83–7.58).

Interpretation: In this population-based study of revascularized patients, we observed a substantial underutilization of cholesterol-lowering medications after revascularization. Our observations suggest an important role for continuity of care in the treatment of cardiovascular patients undergoing revascularization procedures.




This article has been cited by other articles:


Home page
 Card Surg AdultHome page
E. Gongora and T. M. Sundt III
Myocardial Revascularization with Cardiopulmonary Bypass
Card. Surg. Adult, January 1, 2008; 3(2008): 599 - 632.
[Full Text]

Home page
 J Am Coll CardiolHome page
G.B. J. Mancini, M. Etminan, B. Zhang, L. E. Levesque, J. M. FitzGerald, and J. M. Brophy
Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease
J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2554 - 2560.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
L. E. Levesque, J. M. Brophy, and B. Zhang
The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults
Ann Intern Med, April 5, 2005; 142(7): 481 - 489.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
L. E. Levesque, J. M. Brophy, and B. Zhang
The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults
Ann Intern Med, April 5, 2005; 142(7): 481 - 489.
[Abstract] [Full Text] [PDF]